Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

R. Panaccione, J. F. Colombel, W. J. Sandborn, P. Rutgeerts, G. R. D'Haens, A. M. Robinson, J. Chao, P. M. Mulani, P. F. Pollack

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Fingerprint

Dive into the research topics of 'Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science